Related Experiment Video
Updated: Dec 20, 2025

Induction of Paralysis and Visual System Injury in Mice by T Cells Specific for Neuromyelitis Optica Autoantigen Aquaporin-4
Published on: August 21, 2017
Polymyalgia rheumatica following infective triggers or vaccinations: a different subset of disease?
Paolo Falsetti1, Edoardo Conticini1, Caterina Acciai2
1Rheumatology Unit, University of Siena, Italy.
Objectives:
Polymyalgia rheumatica (PMR) is the commonest inflammatory disorder of the elderly; an association with environmental triggers and a deregulated immune response have been described. The aim of this study was to investigate the association of environmental triggers before the onset of PMR.
Material And Methods:
The database of 58 consecutive PMR patients recruited from a single rheumatology secondary care setting was retrospectively analyzed to investigate the frequency of environmental triggers and correlations with clinical characteristics, ultrasound and laboratory data.
Results:
Fifteen PMR patients (26%) described a connection with environmental agents: six PMR patients reported a vaccination, 4 reported a respiratory tract infection, 5 reported seasonal influenza before the onset of the disease. The model of multivariate linear regression which better predicted a shorter time to normalize inflammatory reactants (R 2 = 27.46%, p = 0.0042) comprised the presence of an environmental trigger and a higher PCR. A linear regression analysis confirmed an inverse correlation between PCR at onset and time to normalize inflammatory reactant (r = -0.3031, p = 0.0208). A significant correlation was demonstrated between presence of environmental trigger and shorter time to normalize inflammation (r = -0.5215, p< 0.0001), and lesser frequency of gleno-humeral synovitis on US (r = -0.3774, p = 0.0038).
Conclusions:
Our work describes a correlation between environmental triggers in PMR and higher CRP at diagnosis, faster response to therapy, and milder shoulder synovitis. We may suppose that these patients belong to a more specific subtype of PMR, in whom external stimuli, such as vaccination or infection, may lead to a deregulated response within the context of an impaired senescent immuno-endocrine system.
Insights
Environmental triggers like infections or vaccinations may precede polymyalgia rheumatica (PMR) onset. These triggers correlate with faster treatment response and milder shoulder synovitis in PMR patients.
Area of Science:
- Rheumatology
- Immunology
- Epidemiology
Background:
- Polymyalgia rheumatica (PMR) is a common inflammatory condition in the elderly.
- Environmental factors and immune dysregulation are implicated in PMR pathogenesis.
Purpose of the Study:
- To investigate the association between environmental triggers and the onset of polymyalgia rheumatica.
- To explore correlations between triggers and clinical, ultrasound, and laboratory findings in PMR.
Main Methods:
- Retrospective analysis of 58 PMR patients from a secondary care setting.
- Investigated frequency of reported environmental triggers prior to PMR onset.
- Correlated triggers with clinical characteristics, ultrasound (US), and laboratory data.
Main Results:
- 26% of PMR patients reported environmental triggers (vaccination, respiratory infection, influenza).
- Environmental triggers correlated with a shorter time to normalize inflammatory markers (e.g., CRP).
- Presence of triggers associated with less frequent gleno-humeral synovitis on US.
Conclusions:
- Environmental triggers are linked to higher CRP, faster treatment response, and milder shoulder synovitis in PMR.
- Suggests a distinct PMR subtype triggered by external stimuli in susceptible individuals.
- Highlights the role of environmental factors in PMR development and presentation.
Related Concept Videos
Autoimmune Disorders
Concept and Mechanism of Autoimmune Diseases
The immune...
Myocarditis II: Clinical Features and Diagnostic Tests
Rheumatic Heart Disease I: Introduction
Myocarditis I: Introduction
Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies
Myocarditis III: Medical Management

